The zebra mussel, Dreissena polymorpha, continues to spread from its native range in Eurasia to Europe and North America, causing billions of dollars in damage and dramatically altering invaded aquatic ecosystems. Despite these impacts, there are few genomic resources for Dreissena or related bivalves. Although the D. polymorpha genome is highly repetitive, we have used a combination of long-read sequencing and Hi-C-based scaffolding to generate a high-quality chromosome-scale genome assembly. Through comparative analysis and transcriptomics experiments, we have gained insights into processes that likely control the invasive success of zebra mussels, including shell formation, synthesis of byssal threads, and thermal tolerance. We identified multiple intact steamer-like elements, a retrotransposon that has been linked to transmissible cancer in marine clams. We also found that D. polymorpha have an unusual 67 kb mitochondrial genome containing numerous tandem repeats, making it the largest observed in Eumetazoa. Together these findings create a rich resource for invasive species research and control efforts.
BACKGROUND: Inflammation is a significant risk factor and contributor to the development of cardiovascular disease by driving adaptive and maladaptive responses to cardiac injury. Macrophages are the most abundant immune cells in the heart and play an important role in the remodeling of cardiac tissue. Cardiac resident macrophages (CRMs) are integral components of the myocardium, where they have key roles in inflammation, tissue injury, and remodeling. However, the precise mechanisms by which CRMs regulate remodeling in heart failure remain poorly understood. METHODS: We used in vivo and ex vivo approaches to show that CRMs are the primary source of the chemokine CCL24 (C-C motif chemokine ligand 24) in the heart. To investigate the role of CCL24 on cardiac function following pressure overload, we subjected CCL24-deficient mice to transverse aortic constriction. To determine the role of its receptor CCR3 (C-C chemokine receptor type 3) in fibroblast activation, we used CRISPR (clustered regularly interspaced short palindromic repeats) and Cas9 (CRISPR-associated protein 9) to generate fibroblast-specific CCR3-deficient mice. We used cardiac fibroblasts to determine the direct effects of CCL24 and the signaling pathways downstream of CCR3 required for their activation and proliferation. RESULTS: We identified a subpopulation of CRMs that expresses high levels of CCL24 during pressure overload–induced injury. Following transverse aortic constriction, CCL24 deficiency ameliorated cardiac fibrosis, suggesting a pathological role for CCL24 and revealing that CRMs are a heterogeneous population with dichotomous roles in mediating cardiac remodeling. Mechanistically, CCL24 directly activated cardiac fibroblasts through its sole receptor, CCR3, in an inflammation-independent process. The engagement of the CCR3 receptor promoted fibroblast proliferation and activation via PI3K (phosphoinositide 3-kinase) and the release of the key fibrotic cytokine TGF (transforming growth factor)-β. Following pressure overload, fibroblast-specific deletion of CCR3 improved cardiac function and reduced fibrosis to a degree comparable to that observed in CCL24-deficient mice. Notably, administration of a CCL24-blocking antibody or a CCR3 antagonist enhanced cardiac function in pressure-overloaded mice, underscoring the CCL24-CCR3 axis as a promising therapeutic target for heart failure. CONCLUSIONS: Macrophage-derived CCL24 aggravates fibrosis via the CCR3 receptor, impairing cardiac function in heart failure.
Genetic variations in Idiopathic Pulmonary Fibrosis (IPF) affect survival and outcomes. Current antifibrotic agents are managed based on the patient's reported side effects, although certain single nucleotide polymorphisms (SNPs) might alter treatment response and survival depending on the antifibrotic administered. This study investigated variations in response and outcomes to pirfenidone based on patients-specific genetic profiles. Retrospective clinical data were collected from 56 IPF patients and had blood drawn for DNA extraction between 7/2013 and 3/2016, with the last patient followed until 10/2018. Nine SNPs were selected for pharmacogenetic investigation based on prior associations with IPF treatment outcomes or implications for pirfenidone metabolism. Genetic variants were examined in relation to clinical data and treatment outcomes. Of the 56 patients, 38 were males (67.85%). The average age of IPF at diagnosis was 66.88 years. At the initiation of pirfenidone, the average percent predicted FVC was 70.7%, and the average DLCO percent predicted was 50.02% (IQR 40–61%). Among the genetic variants tested, the TOLLIP rs5743890 risk allele was significantly associated with improved survival, with increasing pirfenidone duration. This finding was observed with CC or CT genotype carriers but not for those with the TT genotype (p = 0.0457). Similarly, the TGF-B1 rs1800470 risk allele was also significantly associated with improved survival with longer pirfenidone therapy (p = 0.0395), even though it was associated with disease progression. This pilot study suggests that in IPF patients, the TOLLIP rs5743890 genotypes CC and CT, as well as TGF-B1 rs 1800470 may be associated with increased survival when treated with pirfenidone.
Inducing stable tolerance to transplants remains a challenge in immunology. Previously, we induced tolerance to allogeneic islets in nonhuman primates by preemptive alloantigen delivery to antigen-presenting cells in situ. Here, mass cytometry phenotyping with incorporated donor-derived MHC-I peptide–loaded MHC-II tetramers revealed accumulation of allospecific CD4 + T cell clusters in the spleen of tolerant recipients. Areg + Tr1 regulatory and terminally exhausted EGFR hi T (Tex) cells represented the predominant allospecific subsets. Trajectory analysis showed that antigen-experienced effector memory T cells differentiated into suppressive Areg + Tr1 and EGFR + TOX + Nur77 + TCF-1 − Tex subsets. Cell-cell communication mapping showed that exhausted and effector memory T cells engaged with allospecific Tr1 cells via the Areg-EGFR axis. Gene silencing studies confirmed that Tr1 cells use Areg-EGFR signaling to drive the metabolic suppression and epigenetic reprogramming of CD4 + T cells through a Nur77-dependent pathway. These findings point to the splenic Areg + Tr1 cell-EGFR + Teff cell axis as a critical immunoregulatory pathway in peripheral transplant tolerance.